China Archives

News and Trends 13 Sep 2022

Himalaya Therapeutics publishes data on cancer treatment

Himalaya Therapeutics has given an interim topline data update from its phase 2 study of HTBA3011 (mecbotamab vedotin) in non-small cell lung cancer (NSCLC) and certain sarcomas. In August, Himalaya’s collaboration partner, BioAtla publicly announced operational updates on the ongoing global clinical trials for HTBA3011 in patients with AXL-positive NSCLC who have previously failed PD-1/L1, […]

September 13, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 8 Sep 2022

Investment of €130M made by Merck’s MilliporeSigma for life-saving therapies

An investment of €130 million ($130 million) has been invested in Molsheim, France to strengthen manufacturing capabilities for single-use assemblies – a key technology for the production of Covid-19 vaccines and other life-saving therapies. The investment was made by MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA. It is the largest ever […]

September 8, 2022 - 2 minutesmins - By Liza Laws

News and Trends 8 Sep 2022

First patient dosed in China trial with drug to treat non-Hodgkin lymphoma

The dosing of the first patient at a clinical trial in China for patients with relapsed/refractory non-Hodgkin lymphoma (NHL) was announced yesterday (September 7). CASI Pharmaceuticals and BioInvent International AB are running the phase 1, dose-escalation and expansion study of BI-1206. The treatment is a fully human monoclonal antibody (mAb) that targets FcyRIIB, in combination […]

September 8, 2022 - 2 minutesmins - By Liza Laws

In Depth 7 Sep 2022

The biggest private biotech investments in August 2022

The healthcare-focused companies Orna Therapeutics, F2G and Sironax bagged the biggest biotech investments in August 2022, with mRNA vaccines, genomics and fermentation technology attracting big funding rounds. As many took a well-deserved vacation in the month of August 2022, the world of biotech remained busy with fundraising. Sit back and browse our lists of the […]

September 7, 2022 - 3 minutesmins - By Jonathan Smith

News and Trends 6 Sep 2022

Innovent starts trial of mazdutide in Chinese adults with obesity

Innovent Biologics, Inc. says the first participant has been successfully dosed in the higher-dose cohort of a phase 2 clinical trial of mazdutide, a glucagon-like peptide 1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist, in Chinese adults with obesity. This randomized, double-blinded, placebo-controlled study was designed to evaluate the efficacy and safety of mazdutide […]

September 6, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 5 Sep 2022

First patient with peripheral T cell lymphoma dosed with Yingli Pharma’s linperlisib

The first patient has been dosed in a phase 2 trial looking at a drug to treat peripheral T cell lymphomas – a heterogenous group of generally aggressive neoplasms. Yingli Pharma made the announcement on Saturday (September 3) that patients were being dosed with linperlisib – a potent inhibitor of the delta isoform of PI3 […]

September 5, 2022 - 2 minutesmins - By Liza Laws

News and Trends 5 Sep 2022

CellOrigin Biotech and Qilu Pharmaceutical to develop CAR-iMAC cell therapy

CellOrigin Biotech (Hangzhou) Co., Ltd. and Qilu Pharmaceutical are to collaborate on strategic global collaborations to develop, manufacture and commercialize ‘off-the-shelf’ induced pluripotent stem cells (iPSC)-derived chimeric antigen receptor macrophages (CAR-iMAC) for cancer immunotherapy. Both companies will work on new drug development and commercialization, and will push CAR-iMAC pipelines forward to clinical trials. “Innovation, and […]

September 5, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 5 Sep 2022

Astellas ‘encouraged’ by menopause symptom treatment results in China

Astellas Pharma Inc. has announced topline results from its phase 3 MOONLIGHT 3 clinical trial in women in mainland China evaluating the long-term safety and tolerability of fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. VMS, characterized by hot flashes and/or night […]

September 5, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 2 Sep 2022

Neukio Biotherapeutics completes financing round for development of cell therapy products

Neukio Biotherapeutics, a Chinese company committed to developing novel cell therapy products, has closed $50 million in a series A-1 funding round. The investment round was led by CD Capital, with the participation of Alwin Capital and Surplus Capital as new investors. Existing shareholders Lilly Asia Ventures, Sherpa Healthcare Partners and IDG Capital have continued […]

September 2, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 1 Sep 2022

Labiotech adds conference and event listings

In the past few months, Labiotech.eu has boosted its coverage range to go global, added a podcast, expanded to three weekly newsletters, introduced special monthly newsletters, and now we’ve added another string to our bow – conference and event listings. The page is designed so visitors can easily jump between months and events. Listings have […]

September 1, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 29 Aug 2022

Strategic collaboration announced in China to accelerate the development of bacterial drugs

A strategic cooperation between Porton Advanced Solutions and Suzhou Royaltech Med Co., Ltd was announced today (August 29). The companies say the collaboration which was agreed earlier in the month (August 19) is set to integrate the resources and capabilities of both parties. The say it will jointly promote the establishment of microbial vectors used […]

August 29, 2022 - 2 minutesmins - By Liza Laws

News and Trends 29 Aug 2022

Sanyou and KangaBio to collaborate on antibody drug development and innovation

Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. and Shanghai KangaBio Co., Ltd. have reached an antibody drug licensing agreement. The subject of the agreement is a monoclonal antibody drug developed by Sanyou Biopharmaceuticals, which grants KangaBio an exclusive license to exploit the antibody for research, development, manufacturing and commercialization of immunotherapy products. Previously, KangaBio and Sanyou Biopharmaceuticals […]

August 29, 2022 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

China

Himalaya Therapeutics publishes data on cancer treatment

Investment of €130M made by Merck’s MilliporeSigma for life-saving therapies

First patient dosed in China trial with drug to treat non-Hodgkin lymphoma

The biggest private biotech investments in August 2022

Innovent starts trial of mazdutide in Chinese adults with obesity

First patient with peripheral T cell lymphoma dosed with Yingli Pharma’s linperlisib

CellOrigin Biotech and Qilu Pharmaceutical to develop CAR-iMAC cell therapy

Astellas ‘encouraged’ by menopause symptom treatment results in China

Neukio Biotherapeutics completes financing round for development of cell therapy products

Labiotech adds conference and event listings

Strategic collaboration announced in China to accelerate the development of bacterial drugs

Sanyou and KangaBio to collaborate on antibody drug development and innovation

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!